Recall alert: Orajel teething swabs pulled from shelves over potential fungal contamination
If you have a stash of teething remedies tucked into your medicine cabinet, it may be time to take a second look. Church & Dwight Co., Inc. has issued a voluntary nationwide recall of several swab-based products—including certain Orajel Baby Teething Swabs—due to possible fungal contamination in the cotton tip component.
The recall also includes two types of Zicam nasal swabs. According to the FDA's official alert, these fungi could pose a health risk, especially for children or individuals with weakened immune systems.
This isn't a reason to panic—but it is a moment to pause and take action.
Related: 1.7 million eggs recalled across 9 states after salmonella outbreak
All lot numbers of the following products are affected:
Orajel Baby Teething Swabs UPC: 310310400002Use: To soothe teething discomfort in babies and toddlers
Zicam Cold Remedy Nasal Swabs UPC: 732216301205Use: Homeopathic swab meant to shorten cold duration
Zicam Nasal AllClear Swabs UPC: 732216301656Use: Nasal cleansing swabs (discontinued in 2024)
Important: This recall does not include other Orajel or Zicam products, such as gels or RapidMelts.
Check your medicine cabinet for any of the products above. Look for the UPC code on the packaging.
Stop using recalled products immediately.
Visit www.churchdwightrecall.com or call 1‑800‑981‑4710 (Mon–Fri, 9 a.m.–5 p.m. ET) for a full refund.
Dispose of the product safely—do not donate or give it away.
Related: Check your fridge: Cucumber recall hits 15 states after salmonella outbreak
The FDA says the risk is highest for individuals with inflamed nasal tissue or weakened immune systems, as the fungal contamination could lead to serious infections, especially in the bloodstream.
But if your baby seems healthy and has shown no unusual symptoms, there's no immediate cause for alarm.
Still, if you've recently used a recalled swab call your pediatrician and mention the recall for guidance.
Recalls like these are unsettling—but they're also a sign that safety systems are working. If you've used these products, take a breath. Take the next step. You're doing the right thing by staying informed and responsive.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBS News
an hour ago
- CBS News
Supergoop! and other mousse sunscreen products may not work, FDA warns
Popular sunscreen products that come in mousse form, such as Supergoop!'s body mousse, may not protect wearers from the sun's harmful UV rays, the U.S. Food and Drug Administration is warning. "Beware of sunscreen products in mousse form because they might not be effective," the FDA said in a post on X after issuing five warning letters to companies that make these types of sunscreens. Additionally, the products can pose a risk to consumers because they are packaged to resemble whipped cream containers, which raises the risk that someone could mistake them for food and ingest them, the FDA said. One warning letter was sent to Vacation Inc., a personal care startup that makes what the company calls "Classic Whip Sunscreens," which it markets as "dessert for your skin." The products are classified as drugs because they are designed to, and marketed as, products that can help prevent sunburn and decrease the risk of skin cancer, the FDA notes. While they are sold as over-the-counter drugs, they have not received the required FDA approval, according to the agency's letter. "There are no FDA-approved applications in effect for your drug products," the letter states. The products are also "misbranded" as they are packaged in containers that resemble food canisters, according to the FDA. "Packaging drug products in containers that resemble food containers commonly used by adults and children can mislead consumers into mistaking the products for food, which is of particular concern as this increases the risk of accidental ingestion," the letter reads. Vacation did not immediately respond to a request for comment. Supergoop!, a popular personal care company, also received an FDA warning letter, which informs companies that they have 15 days to address any violations the agency has identified. Supergoop! did not immediately respond to CBS News' request for comment. Supergoop!'s "Play SPF 50 Body Mousse" sunscreen product, also an over-the-counter drug product, lacks FDA approval and violates marketing regulations, according to the letter. Other companies that make mousse sunscreen products, and which received FDA warning letters, include Kalani Sunwear, Botao Baby and Tizo Skin, which also make mousse sunscreen products. None of the companies have responded to CBS News' inquiry about the FDA's warnings.
Yahoo
3 hours ago
- Yahoo
Wegmans recalls cheese products due to potential listeria contamination
Wegmans is recalling its brand of medium camembert cheese and products that contain it due to potential listeria contamination, which can lead to serious illness. In an alert Wednesday, the U.S. Food and Drug Administration said the affected items, which were sold between July 1 and Aug. 12, include: Wegmans Medium Camembert Soft Ripened Cheese, 8.8 OZ — UPC: 77890-53515 with best by dates of 7/26/25, 8/12/25, and 8/19/ Assorted Cheese Flight, 1 LB — UPC: 2-77100-00000-0. Wegmans Grilling Camembert with Tapenade & Roasted Tomatoes, 10 OZ — UPC: 2-77297-00000-0. Wegmans Caramel Apple Pecan Topped Brie Cheese, 13 OZ — UPC: 2-77645-00000-3. The affected products were sold at Wegmans in the following locations: ConnecticutDelawareMarylandMassachusettsNew JerseyNew YorkNorth CarolinaPennsylvaniaVirginiaWashington, D.C. So far, no illnesses have been reported to Wegmans or its supplier, but officials say customers should not consume the products and can return them for a full refund. Listeria infections are caused by eating food contaminated with the bacteria called Listeria monocytogenes. In healthy individuals, short-term symptoms may include high fever, severe headache, stiffness, nausea, abdominal pain and diarrhea. But for young children, the elderly and those with weakened immune systems, the infection can be serious and sometimes fatal. Listeria infection can also cause miscarriages and stillbirths in pregnant women. President Trump says meeting with Russia's Putin is not to broker peace deal in Ukraine Could Tropical Storm Erin become the first Atlantic hurricane of 2025? Trump claims "land swapping" between Russia, Ukraine will happen Solve the daily Crossword
Newsweek
3 hours ago
- Newsweek
Gen Z and Millennials Have Differing Views on Ozempic
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Gen Z and millennials have radically different views on GLP-1s like Ozempic and how much they want the weight loss and diabetes drugs regulated, according to a new report from GLP-1 prescription weight loss company Levity. While 40 percent of current and recent GLP-1 (glucagon-like peptide-1) users said the current regulations are fair, 28 percent want fewer rules and 22 percent said there should be more. But in the millennial age group, users tend to want less regulation, while Gen Z leaned toward more. Why It Matters GLP-1s, which are injectable drugs that mimic hormones to reduce blood sugar and promote weight loss, have skyrocketed in popularity in recent years. Popular products, including Ozempic, Mounjaro, Wegovy and Zephound, have been a game changer for many Americans who are obese or have type 2 diabetes. However, stricter FDA rules are now in effect, banning certain compounded GLP-1s and making it more difficult for many Americans to secure the drugs, especially if using it for weight loss reasons. Ozempic is medicine for adults with type 2 diabetes. Ozempic is medicine for adults with type 2 diabetes. Steve Christo - Corbis/Corbis via Getty Images What To Know The Gen Z and millennial response to the stricter FDA rules have been notably different, according to Levity. At 31 percent, millennials were the most likely to favor fewer GLP-1 regulations compared to 19 percent of the group who wanted more. Gen Z, meanwhile, favored stricter rules at 37 percent, while 32 percent wanted fewer. "Millennials are more likely to be prescribed a GLP-1 as compared to Gen Z; therefore, it is not surprising that millennials desire less regulation on these drugs," Richard Frank, MD, MHSA, and chief medical officer at Vida Health, told Newsweek. "Having said that, the regulatory environment surrounding compounded agents, in general, and compounded GLP-1s, specifically, is not as rigorous as it is for branded and generic drugs. Therefore, compounded drugs carry unknown risks that more regulated medications do not." Because semaglutide is no longer on the FDA shortage list, compounding it can carry legal risks. Already, the effects are being felt, as 17 percent of GLP-1 users said it has become harder to get their medication since the FDA tightened rules on compounded semaglutide, Levity reported. There was also a difference in how the generations viewed their use of the drugs. While 75 percent of GLP-1 users believed they'll still be on their treatment plan a year from now, Gen Z was the least likely to think so, at 58 percent. What People Are Saying Board-certified endocrinologist Dr. Caroline Messer told Newsweek: "Millennials, many of whom are now managing midlife weight and metabolic health concerns, may see GLP-1s as a practical tool and want fewer barriers. Gen Z, meanwhile, is generally more wary of long-term unknowns, hence leaning toward more safeguards. Broadly, Americans are divided but lean toward keeping current regulations." Richard Frank, MD, MHSA, and chief medical officer at Vida Health, told Newsweek: "From a business perspective, limiting access to compounded drugs when branded drugs are available protects the drug companies' patents. This protection provides the financial incentive for drug companies to develop innovative new therapies." What Happens Next The long-term effects of GLP-1 medication use are so far unclear. A recent study discovered a new link between taking GLP-1 drugs and elevated risk of pancreatitis and kidney conditions, including kidney stones. And GLP-1 medications have also been associated with a higher risk of digestive problems, including nausea, vomiting, diarrhea and even stomach paralysis in rare cases.
